Abstract: In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In another aspect, the invention provides methods and compositions for increasing the survival of red blood cells in a subject suffering from paroxysmal nocturnal hemoglobinuria by administering to the subject a composition comprising an amount of at least one of a MASP-1 inhibitory agent and/or a MASP-3 inhibitory agent effective to increase the survival of red blood cells.

Abstract: The present disclosure relates to a caster, having a housing, having an axle pin which is arranged in a housing opening which is oriented substantially horizontally, and on which at least one wheel is mounted, having, at the top, a pin opening oriented substantially vertically, for receiving a pivot pin, and having a braking device which brakes the at least one wheel, wherein the housing opening for the axle pin allows limited vertical displaceability of the axle pin and the braking device comprises at least one resilient housing part which acts on the axle pin. In order to provide a mechanically reliable braking device, the braking device is additionally provided with at least one spring element which cooperates with the at least one resilient housing part and amplifies the effect of its braking force and/or increases the mechanical load-bearing capacity of the at least one resilient housing part.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: The invention relates to a method for producing an ultrasound sensor (20) for a motor vehicle, in which method, for the ultrasound sensor (20), a diaphragm (23) for emitting ultrasound signals in an emitting direction (21) and a sensor housing (24) are provided, in and/or on which sensor housing the diaphragm (23) is fastened, wherein the sensor housing (24) has a front side (25), which points in the emitting direction (21) of the diaphragm (23), and a rear side (26), which points in a rearward direction (27) which is opposite to the emitting direction (21), and wherein the sensor housing (24) is, on the rear side (26), formed with a rear-side installation opening (29) for components of the ultrasound sensor (20), wherein the diaphragm (23) is inserted into the sensor housing (24) through the rear-side installation opening (29) in the emitting direction (21), and said diaphragm is placed, through an interior space (30) of the sensor housing (24), into an installed position at the front side (25) of the sensor

Abstract: An ultrasonic sensor (1) comprises a housing (2) and a diaphragm (4), to which a piezo-electric element (6) is fastened, and an electric connector region (8) which has an earth connector (24). A layer made from an electrically non-conducting material is arranged between the diaphragm (4) and the piezo-electric element (6), and the diaphragm (4) is connected to the earth connector (24) in an electrically conducting manner.

Abstract: In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

Abstract: A method for producing an ultrasound sensor for a vehicle is disclosed. A diaphragm for emitting ultrasound signals in an emitting direction and a sensor housing are provided for the sensor, where the diaphragm is fastened on the sensor housing, where the housing has a front side, which points in the emitting direction, and a rear side, which points opposite the emitting direction, and where, on the front side, the housing is formed with a front-side opening for the diaphragm, where the front side of the housing is connected to a cap which is composed of a foil and by way of which the front-side opening of the housing is covered in the emitting direction, where the diaphragm is inserted at least regionally into a receptacle of the cap and, a front side of the diaphragm, which points in the emitting direction, is connected to a base of the receptacle.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: Device for centerless round grinding of round, cylindrical work pieces, having a grinding wheel with an axis of rotation, a regulation wheel for pressing of the work piece against the grinding wheel with an axis of rotation, a workrest blade for putting on the work piece and/or a truing device for the grinding wheel and/or a truing device for the regulation wheel, arranged in such a way on a machine bed, in particular in an assembly surface inclined in the space, that the grinding wheel and the regulation wheel and the workrest blade touch the work piece at the moment of grinding, whereas the work piece is arranged in a grinding gap being formed by the adjoining regulation wheel, grinding wheel and workrest blade, whereas the grinding wheel and/or the regulation wheel and/or the truing device for the grinding wheel and/or the truing device for the regulation wheel respectively are arranged on a hydraulic and/or electromotive driven carriage, which is at least longitudinally adjustable along a longitudinal mo

Abstract: The invention relates to a method for producing an ultrasound sensor (20) for a motor vehicle, in which method, for the ultrasound sensor (20), a diaphragm (23) for emitting ultrasound signals in an emitting direction (21) and a sensor housing (24) are provided, in and/or on which sensor housing the diaphragm (23) is fastened, wherein the sensor housing (24) has a front side (25), which points in the emitting direction (21) of the diaphragm (23), and a rear side (26), which points in a rearward direction (27) which is opposite to the emitting direction (21), and wherein, on the front side (25), the sensor housing (24) is formed with a front-side opening (28) for the diaphragm (23), wherein the front side (25) of the sensor housing (24) is connected to a cap (52) which is composed of a foil and by way of which the front-side opening (28) of the sensor housing (24) is covered in the emitting direction (21), wherein the diaphragm (23) is inserted at least regionally into a receptacle (53) of the cap (52) and, he

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: A hydraulic unit includes two pressure connections for supplying devices, in particular hydraulic rescue devices, including a first hydraulic circuit with a first pump arrangement and a first pressure connection and a second hydraulic circuit with a second pump arrangement and a second pressure connection, wherein the pump arrangements are driven at the same time by a common drive, and wherein by a first valve switch the first hydraulic circuit can be connected to the second hydraulic circuit and by a second valve switch the second hydraulic circuit can be connected to the first hydraulic circuit. The valve switches include a spring acting in the direction of an initial position and from the first hydraulic circuit or from the second hydraulic circuit a first control line runs to the first valve switch and from the second hydraulic circuit or from the first hydraulic circuit a second control line runs to the second valve switch.

Abstract: The invention relates to a method for producing an ultrasound sensor (20) for a motor vehicle, in which method, for the ultrasound sensor (20), a diaphragm (23) for emitting ultrasound signals in an emitting direction (21) and a sensor housing (24) are provided, in and/or on which sensor housing the diaphragm (23) is fastened, wherein the sensor housing (24) has a front side (25), which points in the emitting direction (21) of the diaphragm (23), and a rear side (26), which points in a rearward direction (27) which is opposite to the emitting direction (21), and wherein, on the front side (25), the sensor housing (24) is formed with a front-side opening (28) for the diaphragm (23), wherein the front side (25) of the sensor housing (24) is connected to a cap (52) which is composed of a foil and by way of which the front-side opening (28) of the sensor housing (24) is covered in the emitting direction (21), wherein the diaphragm (23) is inserted at least regionally into a receptacle (53) of the cap (52) and, he

Abstract: The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.

Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

Abstract: In one aspect, the invention provides methods for reducing proteinuria in a human subject suffering, or at risk of developing Immunoglobulin A Nephropathy (IgAN). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory antibody effective to inhibit MASP-2-dependent complement activation.